Brief: European Patent Granted For ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator Var 200 For Use In Patients With Diabetic Nephropathy/Diabetic Kidney Disease
07/07/2023 13:18
July 7 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* EUROPEAN PATENT GRANTED FOR ZYVERSA THERAPEUTICS' LEAD
ASSET,
CHOLESTEROL EFFLUX MEDIATOR™ VAR 200 FOR USE IN PATIENTS WITH
DIABETIC NEPHROPATHY/DIABETIC KIDNEY DISEASE
Source text for Eikon: ID:nGNXbH6ckB
Further company coverage: ZVSA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing